FDA Approves Expanded Indication for Merck ’s Keytruda (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Keytruda Is Now Approved for the Treatment of Patients With Recurrent or Metastatic or Locally Advanced cSCC That Is Not Curable by Surgery or Radiation
KENILWORTH, N.J.--(BUSINESS WIRE) July 6, 2021 -- Merck (NYSE: MRK), known as MSD...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Merck | Skin Cancer | Squamous Cell Carcinoma